(Q35601648)

9 August 2017

1 reference

title

Challenges in the endocrine management of breast cancer (English)

1 reference

9 August 2017

Henning T Mouridsen

1

1 reference

9 August 2017

Carsten Rose

series ordinal

2

1 reference

9 August 2017

Angela H Brodie

series ordinal

3

1 reference

9 August 2017

Ian E Smith

series ordinal

4

1 reference

9 August 2017

language of work or name

1 reference

1 August 2003

1 reference

9 August 2017

1 reference

9 August 2017

volume

12 Suppl 2

1 reference

9 August 2017

page(s)

S2-19

1 reference

Estrogens in plasma and fatty tissue from breast cancer patients and women undergoing surgery for non-oncological reasons

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Production and actions of estrogens

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Regulation of aromatase activity within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

1 reference

7 January 2021

Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen resistant breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Comprehensive pharmacology and clinical efficacy of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Studies on the mechanism of estrogen biosynthesis in the rat ovary--I

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Aromatase inhibitors in advanced breast cancer: mechanism of action and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Aromatase inhibitors and inactivators in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Aromatase within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Endocrine therapy in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Aromatase inhibitors and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Antiaromatase agents: preclinical data and neoadjuvant therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Letrozole as primary medical therapy for locally advanced and large operable breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Endocrine and clinical endpoints of exemestane as neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Use of aromatase inhibitors in the adjuvant treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Aromatase inhibitors in the treatment and prevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Risks versus benefits in the clinical application of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2803%2980158-3

7 January 2021

10.1016/S0960-9776(03)80158-3

Identifiers

DOI

1 reference

9 August 2017

1 reference